Biocon Expects Stronger Performance in FY27, Sees Growth in Biosimilars Business
New Delhi, India – August 6: Biocon, a biopharmaceutical company, expects to deliver a stronger performance in the fiscal year 2027, with growth momentum set to accelerate during the year. The company’s management commentary in its Q1 FY27 investor presentation, released on Thursday, stated that a meaningful pickup in the second half is expected for its biosimilars business.
According to the presentation, Biocon has started FY27 on a steady footing and is well-positioned to deliver stronger performance, supported by recent product launches, expanded manufacturing capacity, and continued momentum in its biosimilars business. The company also noted that recent launches and market access progress provide visibility for a stronger second half of the financial year.
In its Q1 FY27 earnings release, Biocon reported a consolidated net profit of Rs 141 crore for the quarter ended June 30, 2026, compared to Rs 31 crore in the year-ago period. Revenue from operations rose 10% year-on-year to Rs 4,336 crore, while total income increased 9% to Rs 4,391 crore. EBITDA stood at Rs 902 crore with an EBITDA margin of 21%.
The company’s biopharma business remained the key growth driver during the quarter, with revenue rising 17% year-on-year to Rs 3,615 crore. Biosimilars revenue grew 16% to Rs 2,855 crore, while generics revenue increased 21% to Rs 760 crore. However, services revenue declined 16% year-on-year to Rs 736 crore.
The growth in the biosimilars business was led primarily by the North American market. The recent approval of the second insulin drug product line in Malaysia is expected to double manufacturing capacity and support future growth. For the generics business, generic liraglutide was a key growth driver across multiple markets, including the United States, while margin improvement was driven by operating leverage and cost-efficiency initiatives.
Biocon also stated that it does not expect any material increase in competitive intensity in its generics business. The company’s investor presentation and earnings release provide a positive outlook for FY27, with expectations of stronger performance and growth in the biosimilars business.
Article and image source: malaysiasun.com
